140 related articles for article (PubMed ID: 36123781)
1. Targeted Delivery of PD-L1-Derived Phosphorylation-Mimicking Peptides by Engineered Biomimetic Nanovesicles to Enhance Osteosarcoma Treatment.
Wu W; Guo H; Jing D; Zhang Z; Zhang Z; Pu F; Yang W; Jin X; Huang X; Shao Z
Adv Healthc Mater; 2022 Dec; 11(23):e2200955. PubMed ID: 36123781
[TBL] [Abstract][Full Text] [Related]
2. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.
Liu Z; Wen J; Hu F; Wang J; Hu C; Zhang W
Cancer Sci; 2022 Feb; 113(2):432-445. PubMed ID: 34927311
[TBL] [Abstract][Full Text] [Related]
5. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
Liu Z; Wen J; Wu C; Hu C; Wang J; Bao Q; Wang H; Wang J; Zhou Q; Wei L; Shen Y; Zhang W
Aging (Albany NY); 2020 Jan; 12(2):1213-1236. PubMed ID: 31981455
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1/PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma.
Kushlinskii NE; Alferov AA; Boulytcheva IV; Timofeev YS; Korotkova EA; Khvan OT; Kuzmin YB; Kuznetsov IN; Bondarev AV; Shchupak MY; Sokolov NY; Efimova MM; Gershtein ES; Sushentsov EA; Aliev MD; Musaev ER
Klin Lab Diagn; 2020 Dec; 65(11):669-675. PubMed ID: 33301655
[TBL] [Abstract][Full Text] [Related]
8. NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.
Nuytemans L; Sys G; Creytens D; Lapeire L
Acta Clin Belg; 2021 Apr; 76(2):162-167. PubMed ID: 31635553
[No Abstract] [Full Text] [Related]
9. Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma.
Zhang L; Xue L; Wu Y; Wu Q; Ren H; Song X
Bioengineered; 2021 Dec; 12(2):9520-9530. PubMed ID: 34699324
[TBL] [Abstract][Full Text] [Related]
10. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.
Liu X; He S; Wu H; Xie H; Zhang T; Deng Z
Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288
[TBL] [Abstract][Full Text] [Related]
11. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Vesicle-Mediated IL-1 Signaling in Response to Doxorubicin Activates PD-L1 Expression in Osteosarcoma Models.
Yati S; Silathapanasakul A; Thakaeng C; Chanasakulniyom M; Songtawee N; Porntadavity S; Pothacharoen P; Pruksakorn D; Kongtawelert P; Yenchitsomanus PT; Chanmee T
Cells; 2022 Mar; 11(6):. PubMed ID: 35326493
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-519d-3p antagonizes osteosarcoma resistance against cisplatin by targeting PD-L1.
Wang J; Zhang Z; Qiu C; Wang J
Mol Carcinog; 2022 Mar; 61(3):322-333. PubMed ID: 34780678
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
[TBL] [Abstract][Full Text] [Related]
15. High linear energy transfer carbon-ion irradiation upregulates PD-L1 expression more significantly than X-rays in human osteosarcoma U2OS cells.
Permata TBM; Sato H; Gu W; Kakoti S; Uchihara Y; Yoshimatsu Y; Sato I; Kato R; Yamauchi M; Suzuki K; Oike T; Tsushima Y; Gondhowiardjo S; Ohno T; Yasuhara T; Shibata A
J Radiat Res; 2021 Sep; 62(5):773-781. PubMed ID: 34196706
[TBL] [Abstract][Full Text] [Related]
16. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Zheng B; Ren T; Huang Y; Sun K; Wang S; Bao X; Liu K; Guo W
J Hematol Oncol; 2018 Feb; 11(1):16. PubMed ID: 29409495
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
18. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
19. LRP8 activates STAT3 to induce PD-L1 expression in osteosarcoma.
Zheng S; Wei Y; Jiang Y; Hao Y
Tumori; 2021 Jun; 107(3):238-246. PubMed ID: 33054597
[TBL] [Abstract][Full Text] [Related]
20. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
